Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Slightly Bearish -10

Novo Nordisk's Nanexa Licensing Deal Lands as CFRA Turns Bearish on the GLP-1 Giant

Analyst downgrade Drug approval Licensing agreement AI-generated analysis

🤝 Novo Nordisk signs a EUR 1.165 billion licensing deal with Nanexa for exclusive rights to deploy PharmaShell technology across up to five development programmes.

💰 The agreement includes EUR 615 million in upfront, development, and regulatory milestone payments to the Swedish partner.

📊 CagriSema Phase 3 data shows a 12.4% average weight loss in type 2 diabetes patients, outperforming Eli Lilly's tirzepatide at 9.1%.

⚖️ At a 1.0 milligram dose, CagriSema achieved a 21% weight reduction versus placebo and was superior to 5 mg of tirzepatide in the diabetes study.

📉 CFRA downgrades Novo Nordisk's US depositary receipts from Hold to Sell with a USD 38 price target due to valuation concerns.

📈 Shares finished Friday at EUR 34.05, up 0.2%, but are down 23% year-to-date and 38% below the 52-week high.

🎯 Novo Nordisk aims for risk-adjusted pipeline revenue exceeding DKK 150 billion by 2035 with more than five multi-blockbuster products by 2030.

🔬 The company partners with Anthropic to use Claude AI models, compressing study report production from months to minutes.

🗓️ From 28 September to 2 October, Novo Nordisk will present 44 pieces of research on semaglutide, CagriSema, and zenagamtid at the EASD meeting in Milan.

⚠️ Management concedes that 2030 targets carry uncertainties and do not constitute a binding financial forecast.

Bullish Signals
  • Novo Nordisk secures exclusive rights to deploy Nanexa's PharmaShell technology across up to five development programmes for obesity and type 2 diabetes.
  • The deal with Nanexa is valued at up to EUR 1.165 billion, including EUR 615 million in upfront and milestone payments.
Risk Factors
  • CFRA downgrades Novo Nordisk's US depositary receipts from Hold to Sell with a USD 38 price target.
  • Shares are down 23% year-to-date and sit 38% below their 52-week high amid fierce competitive intensity.
Full Analysis
Novo Nordisk has signed a worldwide licensing and collaboration agreement with Swedish drug delivery specialist Nanexa, centered on the PharmaShell technology. The deal could be worth up to EUR 1.165 billion to Nanexa, including EUR 615 million in upfront payments and milestone fees. Under this arrangement, Novo Nordisk secures exclusive rights to deploy the technology across up to five development programmes focused on long-acting injectables for obesity, type 2 diabetes, and other cardiometabolic conditions. The company is simultaneously advancing its CagriSema pipeline, with recent Phase 3 data showing an estimated average weight loss of 12.4% in adults with type 2 diabetes after roughly 60 weeks, compared to 9.1% for Eli Lilly's tirzepatide. At a 1.0 milligram dose, CagriSema delivered a 21% reduction in weight versus placebo and proved superior to higher doses of tirzepatide in the diabetes study. Novo Nordisk plans to align the regulatory pathway for the type 2 diabetes indication with health authorities. Despite these strategic moves, investor sentiment remains cautious due to competitive pressures and valuation concerns. CFRA recently downgraded Novo Nordisk's US depositary receipts from Hold to Sell with a USD 38 price target, citing that annual revenue growth of 3.6% is already priced into the stock. The company faces challenges in defending its therapeutic edge against rivals like Eli Lilly while managing patent expirations and maintaining operating margins amidst fierce competition in the obesity therapy market.